Gland Pharma Ltd, which is majority-owned by China’s Fosun Group, has received the Securities and Exchange Board of India’s (Sebi) approval to go ahead with its proposed ₹6,000 crore IPO, a person aware of the development told Mint.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
